This study wants to investigate if the combination of a bioactive with a biopassive coating (unfractionated heparin embedded in a phosphorylcholine matrix) combines the beneficial effects of both approaches.
Aim of this study was to assess the prevalence, clinical meaning and modifications of mitral regurgitation (MR) in patients undergoing transcatheter aortic valve implantation (TAVI).
A Food and Drug Administration panel of outside medical experts said a Bayer AG drug, used to control bleeding in patients undergoing heart-bypass surgery, should stay on the U.S. market.
